ArkeaBio Raises $7M for Methane Vaccine Field Trials

ArkeaBio has closed a $7M Series A1 to move its methane-reducing cattle vaccine from animal studies toward broader field programs. Breakthrough Energy Ventures and AgriZeroNZ co-led the financing, which the company announced on September 23, 2025.

The company said the capital will support continued R&D, farmer pilot programs and general operations. ArkeaBio also named Frank Wooten CEO as the business entered a phase where laboratory progress has to become repeatable evidence, a workable regulatory path and a product farmers can adopt.

The wider implication reaches beyond a single vaccine program. Feed additives can reduce cattle methane, but many require controlled, frequent feeding. A vaccine could use animal-health manufacturing, veterinary distribution and routine herd care to reach pasture cattle that spend little or no time inside a feedlot.

What ArkeaBio announced

The Series A1 announcement names Breakthrough Energy Ventures and AgriZeroNZ as co-leads and brings ArkeaBio's company-reported total funding to more than $40M. The company did not disclose its valuation, round terms or a complete participant roster beyond the 2 co-leads.

Breakthrough Energy Ventures previously led ArkeaBio's $12M seed financing in 2022 and its $26.5M Series A in 2024. Axios reported that Grantham Foundation, AgriZeroNZ, Rabo Ventures, Overview Capital and The51 Food & AgTech Fund joined the 2024 round.

AgriZeroNZ's return matters because the fund is backed by the New Zealand government and major agribusinesses and banks. Its mandate centers on agricultural emissions tools that can work while farms remain productive, including pasture-based systems where a daily feed intervention can be difficult to deliver consistently.

Why a vaccine changes the distribution problem

Cattle produce enteric methane when microbes in the rumen convert hydrogen and carbon dioxide into methane during digestion. ArkeaBio's proposed vaccine is designed to stimulate antibodies that reach the rumen through the animal's blood and saliva and interfere with methane-producing microbes.

The scientific mechanism matters, but the commercial thesis sits in the delivery model. Vaccines already move through established animal-health production, distribution and on-farm care. ArkeaBio is trying to place methane mitigation inside that familiar system rather than require farmers to build a new daily feeding routine around the climate product.

That distinction is especially relevant for cattle raised on pasture and rangeland. In a 2024 AgFunderNews interview, then-CEO Colin South argued that vaccination could reach animals outside concentrated feeding systems because the effect is intended to last between doses. The operating advantage remains a hypothesis until efficacy, duration, cost and farmer adoption hold up at larger scale.

What the evidence supports today

ArkeaBio says early studies have produced methane reductions in the 10-15% range. A Global Methane Hub technical review described a reported 12.9% reduction in 10 cattle over 105 days, but it also noted that the experimental conditions and results had not been published in a scientific journal.

That evidence is meaningful as proof of concept and limited as commercial proof. The independent review called for larger and longer studies because vaccine performance can vary with the target methanogen, animal, formulation, dosing schedule, diet and measurement method. ArkeaBio has discussed improving both efficacy and duration, but a target is not a validated outcome.

There is now a field-development signal beyond the company's own website. Emissions Reduction Alberta lists an active $4.9M demonstration project in Kinsella, Alberta, supported by $2.35M in public funding, to test a novel inoculant intended to reduce enteric methane in beef cattle. The project record shows active work, not a completed result.

The leadership handoff behind the round

Frank Wooten joined as CEO with experience in livestock technology and company building. ArkeaBio says Wooten co-founded and led Vence, a virtual-fencing company acquired by Merck Animal Health in 2022. His assignment at ArkeaBio is less about creating another laboratory thesis and more about aligning trials, regulators, capital partners and farmers around a product that still has to earn commercial trust.

Founder Colin South now serves as CBO, preserving the agricultural and bioprocessing context behind the company. CTO Zach Serber joined shortly before the round and brings industrial-biology experience from co-founding Zymergen and working at Amyris. ArkeaBio's current leadership page also lists animal-vaccine veteran Bob Nordgren as VP of Development and Jessica Kates as CFO.

The group now spans science, veterinary product development, finance and livestock operations. That mix fits the next phase, but titles and résumés do not shorten the evidence cycle. The company still has to demonstrate a durable biological effect, a regulator-ready product and economics that reward farmers for using it.

What the $7M must accomplish

ArkeaBio said the financing would help move from animal studies into expanded field programs during 2026-2027. Those programs need to answer practical questions that a laboratory result cannot settle alone: how long the methane reduction lasts, how consistently it appears across animals and production systems, what dosing routine is required, whether meat and milk remain unaffected, and how the product fits into farm economics.

Commercialization also requires clarity about who pays. Farmers administer the product, but food companies, governments and carbon programs may capture part of the climate value. ArkeaBio's distribution advantage becomes more important if those parties can measure the reduction, assign the benefit and compensate the producer without turning vaccination into an administrative burden.

The Series A1 gives ArkeaBio more time and leadership capacity to connect those pieces. The company's opportunity is not simply to make a stronger methane claim in controlled conditions. It is to produce evidence that can travel with the vaccine from a research herd into ordinary farm practice, where the same needle has to satisfy the animal, the farmer, the regulator and the buyer paying for lower-emissions food.